GENE (Genetic Technologies) EV-to-EBIT : (As of Dec. 13, 2024)

View and export this data going back to 2002. Start your Free Trial

What is Genetic Technologies EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Genetic Technologies's Enterprise Value is $3.62 Mil. Genetic Technologies's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil. Therefore, Genetic Technologies's EV-to-EBIT for today is .

The historical rank and industry rank for Genetic Technologies's EV-to-EBIT or its related term are showing as below:

GENE' s EV-to-EBIT Range Over the Past 10 Years
Min: -9.17 Med: -2.14 Max: -0.02
Current: -0.46

During the past 13 years, the highest EV-to-EBIT of Genetic Technologies was -0.02. The lowest was -9.17. And the median was -2.14.

GENE's EV-to-EBIT is ranked worse than
100% of 103 companies
in the Medical Diagnostics & Research industry
Industry Median: 20.68 vs GENE: -0.46

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Genetic Technologies's Enterprise Value for the quarter that ended in Jun. 2024 was $6.51 Mil. Genetic Technologies's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil. Genetic Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was %.

Genetic Technologies EV-to-EBIT Historical Data

The historical data trend for Genetic Technologies's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies EV-to-EBIT Chart

Genetic Technologies Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

EV-to-EBIT

Get a 7-Day Free Trial

-3.83

-7.92

-2.33

-1.81

-0.82

Genetic Technologies Quarterly Data
	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EV-to-EBIT	Get a 7-Day Free Trial															-	-	-	-0.82	-

Competitive Comparison of Genetic Technologies's EV-to-EBIT

For the Diagnostics & Research subindustry, Genetic Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetic Technologies's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's EV-to-EBIT falls into.

Genetic Technologies EV-to-EBIT Calculation

Genetic Technologies's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	3.620	/	0
	=

Genetic Technologies's current Enterprise Value is $3.62 Mil.
Genetic Technologies's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Genetic Technologies (NAS:GENE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Genetic Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2024 )	=	EBIT	/	Enterprise Value (Q: Jun. 2024 )
	=	0	/	6.51386
	=	%

Genetic Technologies's Enterprise Value for the quarter that ended in Jun. 2024 was $6.51 Mil.
Genetic Technologies's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Genetic Technologies EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (NAS:GENE) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

0A4N:UK DU8:Germany GTG:Australia

Address

60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065

Website

https://www.gtglabs.com

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.